Feasibility Study to Evaluate Outpatient Blinatumomab in Subjects With Minimal Residual Disease (MRD) of B-precursor Acute Lymphoblastic Leukemia (ALL)
Amgen
Amgen
Pfizer
Medical College of Wisconsin
Pfizer
ChineseAMS
Novartis
Children's Hospital of Michigan
University of Kansas Medical Center
Novartis
Fox Chase Cancer Center
Novartis
Pfizer